Akèy › Ependimòm
Etid klinik pou Ependimòm ap rekrite nan Etazini
15 etid pou Ependimòm ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
Ap rekriteFaz 1
Laj 6 a 21 · Tout sèks · Mizajou Sep 11, 2026 · NCT07061626Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Ap rekriteFaz 2
Jiska laj 19 · Tout sèks · Mizajou Sep 10, 2026 · NCT01356290HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Ap rekriteFaz 1
36 Months – 22 Years · Tout sèks · Mizajou Sep 4, 2026 · NCT03911388B7-H3.CD28Z.CART in CNS Neoplasms
Ap rekriteFaz 1
Laj 2 a 21 · Tout sèks · Mizajou Sep 3, 2026 · NCT07390539Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT04374305Natural History Study of Patients With Neurofibromatosis Type 2
Ap rekriteEtid obsèvasyon
Laj 8 a 75 · Tout sèks · Mizajou Sep 1, 2026 · NCT00598351PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Aug 12, 2026 · NCT06161519Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
Ap rekrite
12 Months – 39 Years · Tout sèks · Mizajou Aug 11, 2026 · NCT05057702Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Ap rekriteFaz 1/2
Laj 4 a 39 · Tout sèks · Mizajou Jul 20, 2026 · NCT05278208Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
Ap rekriteFaz 1
Laj 1 a 30 · Tout sèks · Mizajou Jun 17, 2026 · NCT06193759ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Ap rekriteFaz 1
Laj 2 a 21 · Tout sèks · Mizajou Jun 11, 2026 · NCT04732065LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
Ap rekriteFaz 1
Jiska laj 22 · Tout sèks · Mizajou May 20, 2026 · NCT03750513Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Ap rekriteFaz 1
Laj 1 a 26 · Tout sèks · Mizajou Apr 13, 2026 · NCT04185038Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Ap rekriteFaz 1
Laj 3 a 25 · Tout sèks · Mizajou Jan 9, 2026 · NCT05106296Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 18, 2025 · NCT04541082Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.